Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 208

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 208
---
 granted, options  
 for 560,000 shares were fully vested upon grant and the remaining 180,000 options are to be vest on April 10, 2025. The options exercisable 
 within ten years from grant date.                                                                                                           |

<div align='center'>F-27</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands, except share and per share data

NOTE 8 – SHAREHOLDERS’ EQUITY (Cont.)

The fair value of the successor’s share
options granted during the period commencing July 24, 2024 through December 31, 2024 was estimated using the black Scholes model using
the following range assumptions:

| Description             |     | December 31, 
 2024         |       |   |
|:------------------------|:----|:-------------|------:|:--|
| Risk-free interest rate |     |              |  4.51 | % |
| Expected volatility     |     |              | 105.6 | % |
| Dividend yield          |     |              |     0 |   |
| Expected term           |     |              |    10 |   |
| Exercise price (USD)    |     |              |   0.3 |   |

| d. | On December 31, 2024, Company’s president and Chief Operating                                                                 
 Officer exercised 2,800,000 option into 2,800,000 common stock. Each option had an exercise price of $0.001 per common stock. |

Share-based
expenses recognized in the financial statements:

|                                     |     | Successor 
 2024      | For the period commencing July 24 
                           through 
                       December 31 |     | Predecessor 
 2024        | For the period commencing January 1 
                             through 
                             July 23 |     | 2023 | For the year ended 
       December 31, |
|:------------------------------------|:----|:----------|----------------------------------:|:----|:------------|------------------------------------:|:----|:-----|-------------------:|
| Research and development expenses   |     |           |                               709 |     |             |                                 710 |     |      |                205 |
| General and administrative expenses |     |           |                               580 |     |             |                                   - |     |      |